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Distribution of Health Care Expenditures
for HIV-Infected Patients
Ray Y. Chen,1 Neil A. Accortt,4 Andrew O. Westfall,2 Michael J. Mugavero,1 James L. Raper,1 Gretchen A. Cloud,4
Beth K. Stone,1 Jerome Carter,1 Stephanie Call,1 Maria Pisu,3 Jeroan Allison,1 and Michael S. Saag1
Departments of 1Internal Medicine, 2Biostatistics, and 3Preventive Medicine and 4Medical Statistics Section, School of Medicine,
University of Alabama at Birmingham, Birmingham, Alabama
(See the editorial commentary by Mayer and Chaguturu on pages 1011–3)
Background. Health care expenditures for persons infected with human immunodeficiency virus (HIV) in the
United State determined on the basis of actual health care use have not been reported in the era of highly active
antiretroviral therapy.
Methods. Patients receiving primary care at the University of Alabama at Birmingham HIV clinic were included
in the study. All encounters (except emergency room visits) that occurred within the University of Alabama at
Birmingham Hospital System from 1 March 2000 to 1 March 2001 were analyzed. Medication expenditures were
determined on the basis of 2001 average wholesale price. Hospitalization expenditures were determined on the
basis of 2001 Medicare diagnostic related group reimbursement rates. Clinic expenditures were determined on the
basis of 2001 Medicare current procedural terminology reimbursement rates.
Results. Among the 635 patients, total annual expenditures for patients with CD4+ cell counts !50 cells/mL
($36,533 per patient) were 2.6-times greater than total annual expenditures for patients with CD4+ cell counts
350 cells/mL ($13,885 per patient), primarily because of increased expenditures for nonantiretroviral medication
and hospitalization. Expenditures for highly active antiretroviral therapy were relatively constant at ∼$10,500 per
patient per year across CD4+ cell count strata. Outpatient expenditures were $1558 per patient per year; however,
the clinic and physician component of these expenditures represented only $359 per patient per year, or 2% of
annual expenses. Health care expenditures for patients with HIV infection increased substantially for those with
more-advanced disease and were driven predominantly by medication costs (which accounted for 71%–84% of
annual expenses).
Conclusions. Physician reimbursements, even with 100% billing and collections, are inadequate to support
the activities of most clinics providing HIV care. These findings have important implications for the continued
support of HIV treatment programs in the United States.
The use of HAART has led to dramatic decreases in
the morbidity and mortality of patients infected with
HIV [1–3]. These benefits, however, come with the ex-
pense of HAART, estimated to be $10,000–$15,000 per
patient per year in the United States [4]. A number of
studies have estimated the monthly health care expen-
ditures incurred by HIV-infected patients and have in-
vestigated the relationship between these expenditures
and CD4+ cell counts [5–15]. Yet, there is no infor-
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mation determined on the basis of actual health care
use, in quantitative terms, regarding actual expenditures
in the contemporary HAART era. Moreover, no prior
studies have been able to evaluate the annual expen-
ditures for a patient whose CD4+ cell count increases
or decreases during the course of therapy.
We investigated questions related to the relationship
among the cost components of care and examined how
a change in clinical status affected cost expenditures
over a period of 1 year. Answers to these questions,
determined in the context of the contemporary HAART
era, are essential if policy makers and third-party payers
are to make informed decisions about the optimal al-
location of scarce resources. To address these questions,
we performed an analysis of expenditures using the
University of Alabama at Birmingham (UAB) Studies
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Table 1. Cost components and expenditures included in a study of patients with HIV infection at the University of Alabama at
Birmingham.
Cost component Expenditures Cost data
Hospital costs Inpatient medications, radiological examinations, labora-
tory studies, and procedures, by Medicare reimburse-
ment rates for diagnostic related group codes
Medicare diagnostic related group, based on hospital
diagnoses
Antiretroviral medications Outpatient antiretroviral medications, by average whole-
sale price
Average wholesale price, using stop and start dates per drug
Nonantiretroviral medications All nonantiretroviral outpatient medications, including an-
tibiotics, by average wholesale price
Average wholesale price, using stop and start dates per drug
Physician/clinic fees Physician fees included inpatient and outpatient physi-
cian professional fees; clinic fees included medication
services (i.e., infusions, injections, and chemotherapy)
and charges for use of space
Medicare reimbursements paid via current procedural
terminology codes for visit
Other outpatient expenditures Outpatient procedures not performed in the HIV outpa-
tient clinic (i.e., laboratory studies, radiological exami-
nations, and outpatient surgeries), home health care,
and hospice care
Medicare reimbursements paid via current procedural
terminology codes
of HIV/AIDS Longitudinal Outcome Metrics database. This
database combines clinical data, laboratory data, and data on
health care use for all of its patients to monitor and measure
outcomes of care over time. Therefore, this database provides
the opportunity to investigate the relationship between health
care expenditures and CD4+ cell counts, to evaluate the con-
tribution of each category of expenditures to overall expen-
ditures, and to quantitate the effect of an increase or decrease
in CD4+ cell count on expenditures.
METHODS
In January 1994, the UAB outpatient HIV clinic initiated an
ongoing database (Studies of HIV/AIDS Longitudinal Outcome
Metrics) that collected clinical information for all patients seen.
Trained medical records personnel used standardized proce-
dures to abstract clinical and treatment data from medical re-
cords daily. Laboratory data were downloaded from the hospital
laboratory system directly into the database. All outside labo-
ratory values were entered into the database manually (quality
control assessments demonstrated an error rate of !5%). Health
care use data were added to the database beginning in March
1999.
All patients included in this study received their primary care
at the UAB HIV clinic, had a baseline CD4+ cell count on 1
March 2000 (90 days), and had at least 1 follow-up clinic
visit or hospitalization between 1 June 2000 and 1 March 2001.
Patients who had a follow-up visit after 1 June 2000 but sub-
sequently died before 1 March 2001 were also included.
Hospitalization, laboratory, procedure, and clinic use data
were obtained from the UAB Health System between 1 March
2000 and 1 March 2001; data pertaining to emergency de-
partment visits that did not result in an inpatient admission
were not included. Health care received outside of the UAB
health system was not captured. An expenditure was defined
as the cost outlay required to pay for any service or medication
used by a patient during the time of observation. Information
on use of clinical services was translated into expenditures
through assignment of cost per unit activity on the basis of
2001 Medicare reimbursement rates [16]. Although nearly 30%
of our patients are uninsured and our usual collection rate is
40%, for analysis purposes, we assumed that all patients had
Medicare insurance, that there was complete billing for all
health care use, and that the collection rate was 100%. Expen-
ditures were broken down by cost component, as shown in
table 1.
Hospitalization expenditures were determined on the basis
of Medicare reimbursement rates for diagnostic related group
codes for each admission [17]. The hospital-associated expen-
ditures included all technical expenditures associated with the
hospital stay, such as inpatient medications, radiological studies,
procedures, and laboratory studies, but did not include phy-
sicians’ professional fees incurred during the hospital stay; both
inpatient and outpatient physician professional fees were in-
cluded in clinic/physician expenditures.
Data on the use of outpatient clinical services was obtained
by a data warehouse query of services rendered using the IDX
database system. This system captures all UAB service activity
related to outpatient professional and technical fees, as well as
use of all outpatient clinics, across the University Health System
(including all subspecialty consultation and mental health vis-
its), except for fees associated with emergency department visits
that do not result in a hospitalization. Outpatient clinic use,
which included level of clinic visits, delivery of outpatient med-
ication services (such as delivery of infusions, injections, and
chemotherapy), and laboratory use, was converted into expen-
ditures on the basis of 2001 Medicare reimbursement rates
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Table 2. Baseline characteristics of the 635 patients from the
University of Alabama at Birmingham HIV outpatient clinic in-





Age, median years (range) 35 (18–66)
Male sex 491 (77.3)
White race 376 (59.2)
Behavioral characteristic
Men who have sex with men 394 (62.0)
Injection drug use 65 (10.2)
Clinical characteristic
CD4+ cell count at baseline,
median cells/mL (range) 367 (2–2671)
CD4+ cell count strata
!50 cells/mL 62 (9.8)
50–199 cells/mL 99 (15.6)
200–249 cells/mL 143 (22.5)
350 cells/mL 331 (52.1)
CD4+ cell count pre-HAART,
median nadir cells/mLa 144
Viral load at baseline,
median log10 copies/mL (range) 2.4 (!1.3–6.0)
Receiving HAARTb 510 (80.3)
History of opportunistic infection 171 (26.9)
Hyperlipidemia 325 (51.2)
Diabetes mellitus 65 (10.2)





NOTE. Data are no. (%) of patients, unless otherwise indicated.
a .np 570
b HAART was defined as any combination of 3 antiretroviral medications.
using current procedural terminology codes [18]. Substance
abuse treatment is provided through a federally funded grant
and was not captured in our outpatient clinic visits. Sensitivity
analyses were conducted to assess the potential impact of the
inclusion of substance abuse treatment, missed emergency
room visits, and missed visits at other facilities on outcomes.
Medication expenditures were based on use data as recorded
in the outpatient medical record. At each patient visit, the clinic
health care provider recorded all changes to the patient med-
ication list, including date of initiation of new medications,
date of discontinuation of previous medications, and dosages.
The changes included all medications prescribed by that pro-
vider or by any other provider as reported by the patient.
Medication, dosage, and start and stop dates were entered into
the clinical database within 24 h after each patient visit. Out-
patient medication infusion and injection expenditures were
included in the physician/clinic expenditures, not in the med-
ication expenditures. Medication expenditures were assigned
on the basis of the 2001 average wholesale price (AWP) for
each medication recorded in the clinic database, incorporating
duration of therapy as calculated through medication start and
stop dates [19]. Although it was recognized that most medi-
cation payment programs often received substantial discounts,
the high degree of variability in discounts between programs
(and even within drug classes) made it impossible to use a
consistent, meaningful discounted price. AWP was chosen as
the standard for this study, because it forms the primary basis
on which discounted pricing is determined. A sensitivity anal-
ysis was conducted to assess the impact of the decision to use
AWP on the reported findings.
Expenditure data were aggregated into two 6-month inter-
vals. Patients were categorized by baseline CD4+ cell count into
4 strata: !50 cells/mL, 50–199 cells/mL, 200–349 cells/mL, and
350 cells/mL. Improvement status was defined by whether a
patient’s CD4+ cell count category at 6 months had changed
relative to the baseline category. Patients were considered to
have experienced improvement if their 6-month CD4+ cell
count moved them into a higher CD4+ cell count stratum, and
their condition was considered to have worsened if they moved
to a lower CD4+ cell count stratum. Patients whose CD4+ stra-
tum did not change were considered to be the same, including
those patients whose CD4+ cell counts remained in the highest
or lowest CD4+ cell count group. Patients were then stratified
by CD4+ improvement status, and annualized expenditures
were determined for each group. Annual costs represented the
sum incurred during both 6-month intervals.
To correct for the nonnormal distribution of the annual cost
data, we transformed the data by taking the natural log of the
annual costs. All analyses were conducted using these trans-
formed data, but results are presented using the actual costs.
Analysis of variance was used to assess for overall significance
of differences in expenditures between CD4+ cell count cate-
gories, and Duncan’s multiple range test was used to control
for the analysis of variance pair-wise comparisons at the .05
level. Statistical analyses were performed using SAS software,
version 8.2 (SAS Institute).
RESULTS
Of the 1041 patients seen between 1 March 2000 (90 days)
and 1 March 2001, 635 met the inclusion criteria; 309 patients
did not have a baseline CD4+ cell count within the specified
time window, and 97 patients did not have a follow-up visit
or hospitalization. The baseline demographic characteristics of
this cohort are listed in table 2. These patients were predom-
inantly white men who had sex with men, and most of the
patients had good virologic responses to HAART (median viral
load, 2.4 log10 copies/mL). More than 50% of the patients had
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Table 3. Mean annual expenditure per patient by cost component and CD4+ cell count category for 635 patients from the University
of Alabama at Birmingham HIV outpatient clinic.
CD4+ cell count category
No. of
patients













!50 cells/mL 62 $36,532 (100) $10,855 (30) $14,882 (41) $8353 (23) $1909 (5) $533 (1)
50–199 cells/mL 99 $23,864 (100) $11,862 (50) $6685 (28) $3369 (14) $1416 (6) $532 (2)
200–349 cells/mL 143 $18,274 (100) $11,935 (65) $3452 (19) $1186 (7) $1365 (7) $336 (2)
350 cells/mL 331 $13,885 (100) $9407 (68) $1855 (13) $1408 (10) $930 (7) $285 (2)
All 635 $18,640 (100) $10,500 (56) $4240 (23) $2342 (13) $1199 (6) $359 (2)
a Other outpatient costs include outpatient radiological examinations, laboratory tests, procedures, and home health care.
CD4+ cell counts 350 cells/mL. Twenty patients died during
the analysis period; the median duration of follow-up for these
patients was 7 months.
The annual expenditure data were aggregated into two 6-
month intervals, with the mean 1-year totals for each CD4+
cell count category listed in table 3. The distribution of the
total expenditures differed significantly across CD4+ cell count
categories; patients with CD4+ cell counts !50 cells/mL gener-
ated $36,532 per patient per year in expenditures, whereas pa-
tients with CD4+ cell counts 350 cells/mL generated expen-
ditures of $13,885 per patient per year ( ). In contrast,P ! .0001
viral load strata were less discriminatory, with strata of !50
copies/mL, 50–4999 copies/mL, 5000–99,999 copies/mL, and
1100,000 copies/mL resulting in expenditures of $17,142,
$17,176, $18,295, and $28,825 per patient per year, respectively.
The increased expenditures for patients with low CD4+ cell
counts were predominantly attributable to increased nonantir-
etroviral medication and hospitalization expenditures (table 3;
figure 1A and 1B), although all expenditures were significantly
higher for patients with CD4+ cell counts !50 cells/mL than
they were for patients with CD4+ cell counts 350 cells/mL
( ). Compared with patients with CD4+ cell countsP .0006
350 cells/mL, patients with CD4+ cell counts !50 cells/mL had
hospitalization expenditures that were almost 6-fold greater and
nonantiretroviral medication expenditures that were almost 8-
fold greater. Fifty-one percent of nonantiretroviral medication
costs for patients with CD4+ cell counts of !50 cells/mL were
due to antimicrobials, compared with only 17% for patients
with CD4+ cell counts 350 cells/mL. These expenditures were
distributed evenly over the population of patients with CD4+
cell counts !50 cells/mL and were not unduly influenced by
outliers. Because antiretroviral medication costs remained rel-
atively constant across CD4+ cell count strata ($9407–$11,935
per patient per year), the proportion of overall expenditures
attributable to use of antiretroviral therapy more than doubled
for patients with CD4+ cell counts 350 cells/mL (68%), com-
pared with patients with CD4+ cell counts !50 cells/mL (30%).
Two percent or less of all expenditures was due to physician/
clinic fees, with an average annual expenditure of !$400 per
patient per year. This figure assumed that all patients had Med-
icare health insurance and that the collection rate per physician/
clinic encounter was 100%.
To assess the impact of a decrease in immunologic status
during the study period, expenditures were stratified by the
change in each patient’s CD4+ cell count status between baseline
and 6 months later (figure 1B). A decrease in CD4+ cell count
category was always associated with increased expenditures, but
this increase was statistically significant only for patients whose
baseline CD4+ cell count was in the 50–199 cells/mL category
( ). The differences in expenditures for these patientsPp .003
are shown in figure 1B, in which patients with a baseline CD4+
cell count between 50–199 cells/mL were stratified by cost com-
ponent and improvement status. In a manner similar to that
seen with total expenditures, the increased expenditures asso-
ciated with a decline in CD4+ cell count were predominantly
attributable to nonantiretroviral medications ( ) andPp .03
hospitalizations ( ). Expenditures for other cost com-Pp .05
ponents were not significantly different.
We conducted a similar analysis of data from 1 March 1999
through 1 March 2000 (data not shown) and found very similar
results for the mean annual expenditures, CD4+ cell count ex-
penditure distribution, and contribution of expenditure cate-
gory to overall expenditures. Because the data from 2000–2001
were more recent, we elected to present only those results.
However, this does show that our results were consistent over
a 2-year period.
Sensitivity analyses demonstrated little impact on the overall
findings when adjustments were made for missing data re-
garding emergency room visits, substance abuse/mental health
visits, visits at other health care facilities, or the use of full AWP
in our study (table 4). Approximately 25% of our patients have
substance abuse/mental health problems that warrant outpa-
tient visits for therapy. If liberal adjustments are made in our
outpatient use data to adjust for the missing data regarding
emergency room visits, visits to other facilities, and substance
abuse/mental health visits such that the total outpatient costs
Figure 1. A, Assessment of changes in annual expenditures for patients whose CD4+ cell count status increased ( ), decreased ( ),np 386 np 102
or remained unchanged ( ) between baseline (1 March 2000) and 6 months (1 September 2000). A decrease in CD4+ cell count category wasnp 134
associated with a significant increase ( ) in annual cost among patients initially assigned to the group of patients with CD4+ cell counts ofPp .003
50–199 cells/mL. The cost differences in other CD4+ cell count categories were not significantly different ( ). B, Assessment of the source ofP 1 .2
expenditures for patients initially assigned to the CD4+ cell count 50–199 cells/mL group whose CD4+ cell count category increased , decreased, or
stayed the same between baseline and 6 months. Nonantiretroviral medication ( ) and hospital costs ( ) for patients with a decreasePp .03 Pp .05
in CD4+ cell count category were significantly increased, compared with costs for patients with an increase in CD4+ cell count category. Differences
for other cost components were not significantly significant. ART, antiretroviral therapy.
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Table 4. Sensitivity analyses performed to assess impact of lower medication average wholesale pricing (AWP) and accounting for
the costs of emergency room (ER) visits, substance abuse/mental health care costs, and the costs of unaccounted visits at other
facilities.
Analysis









Initial $14,740 (79.1) $2342 (12.6) $1558 (8.4) $18,640 (100)
Incorporating AWP discounted 25% $11,055 (73.9) $2342 (15.7) $1558 (10.4) $14,955 (100)
Incorporating ER visitsa $14,740 (75.9) $2342 (12.1) $2337 (12.0) $19,419 (100)
Incorporating ER visits, substance abuse /mental
health care costs, and unaccounted visitsb $14,740 (73.0) $2342 (11.6) $3116 (15.4) $20,198 (100)
Incorporating AWP discounted 25%, ER visits,
and substance abuse/mental health care costsc $11,055 (70.3) $2342 (14.9) $2337 (14.9) $15,734 (100)
Combination of AWP discounted 25%, ER visits,
substance abuse/mental health care costs, and
unaccounted visitsb $11,055 (66.9) $2342 (14.2) $3116 (18.9) $16,513 (100)
NOTE. The costs of ER visits, substance abuse/mental health care costs, and the costs of unaccounted visits at other facilities were each evaluated at 25%–
50% of total outpatient costs.
a Cost of emergency room visits was evaluated at 25%–50% of total outpatient costs.
b Cost was evaluated at 100% of total outpatient costs.
c Cost was evaluated at 50% of total outpatient costs.
were doubled (from ∼$1300 to ∼$2600 per patient per year),
the impact on our overall findings would be minimal. Medi-
cation costs would account for 73% (compared with 79%) of
total costs, and HIV provider reimbursement would not in-
crease, because these services are provided elsewhere. To explore
the impact of discounted AWP pricing on our study findings,
we reanalyzed our findings using a discount of 25% below AWP,
a common discount for federal programs, such as the AIDS
Drug Assistance Program (ADAP). With this adjustment, over-
all annual medication costs decreased from $14,740 to $11,055
per patient. Similarly, the overall expenditures decreased from
$18,640 to $14,955 per patient per year. However, even in this
scenario, medications still comprised 74% of overall expendi-
tures, compared with 79% as determined in our primary analy-
sis using full AWP. Using both a discount of 25% below AWP
and a doubling of outpatient expenditures to account for miss-
ing visits, medications still comprise 67% of total health care
expenditures.
DISCUSSION
In this study, we determined per patient expenditures of care
by directly measuring health system and medication use in a
population of patients receiving primary HIV care at an aca-
demic medical center clinic in the southeastern United States.
Our findings demonstrate a dramatic association between an-
nual per patient expenditures and CD4+ cell counts, with pa-
tients in the lowest CD4+ category expending 2.6 times more
health care dollars per year than patients in the highest CD4+
cell count category. The single most expensive cost component
was medications, accounting for 71%–84% of the overall health
care costs, depending on stage of disease. Antiretroviral therapy
represented 56% of the overall costs; however, the improvement
in clinical status associated with successful antiretroviral ther-
apy, as demonstrated by increases in CD4+ cell count, led to a
reduction in health care expenditures in other areas. In par-
ticular, the sickest patients (CD4+ cell count, !50 cells/mL) re-
quire 8-fold more nonantiretroviral medication expenditures
and 6-fold more hospitalization expenditures than do the
healthiest patients (CD4+ cell count, 350 cells/mL). The most
striking finding in this study, however, was the low expenditures
for health care services provided by HIV physicians and clinics.
Taken together, these findings demonstrate the relative cost of
care in a fashion that informs policy makers, payers, and health
care administrators.
To quantitate the reduction in expenditures associated with
an increase in CD4+ cell count, we assessed the impact of
changes in CD4+ cell count strata on annual expenditures dur-
ing the year-long period of observation. Compared with pa-
tients who remained in the same CD4+ cell count stratum,
patients who moved to a higher stratum during the year had
lower annual expenditures, whereas patients who moved to a
lower stratum experienced higher expenditures. Because anti-
retroviral drug effects principally drive improvements in CD4+
cell counts, these findings further demonstrate the clinical and
economic benefit of antiretroviral therapy among patients for
whom therapy is currently recommended [20, 21]. Because
these data do not account for indirect costs, such as lost wages
for patients and caregivers, we speculate that the true economic
benefit of increased CD4+ cell count status would likely be
substantially greater. These data strongly validate the activity
of federal programs, such as ADAP, in providing antiretroviral
medications to patients who do not have prescription drug
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insurance coverage. Yet, ADAP programs in many states con-
tinue to experience budget shortfalls, and many patients are in
jeopardy of not having access to needed medications [22, 23].
Despite the value of antiretroviral medications in increasing
CD4+ cell counts and thereby decreasing costs, our data also
highlight the large discrepancy between expenditures for med-
ications and expenditures for other health care services. Most
striking was the paucity of expenditures for clinic and physician
services, representing 2% of all expenditures regardless of
CD4+ cell count (range, $285–$533 per patient per year). This
amount includes physician fees for inpatient as well as out-
patient services, making the finding even more striking. As
patient outcomes have improved, owing in large part to the
proper use of antiretroviral therapy, the number of inpatients
has declined, and the contribution of inpatient physician re-
imbursement is only a fraction of physician reimbursement.
Indeed, the inpatient physician component was mostly con-
centrated among patients with CD4+ cell count !50 cell/mL
and contributed little to the overall expenditures.
We utilized AWP to assign costs to medications. Because
ADAP and most third-party payers receive substantial discounts
below AWP to purchase medications, our findings likely over-
estimate the actual contribution of medication expenditures to
overall costs. We chose AWP for the final analysis because of
the high degree of variability in the AWP discount, which varies
widely from state to state and program to program. However,
even when such discounts are factored in, our conclusions do
not change. For example, in our sensitivity analysis, discounting
the AWP by 25% (a common discount for federal programs
such as ADAP) reduced overall expenditures, but medications
still comprised 74% of overall costs. The sensitivity analyses
addressed several other limitations of our study, including the
absence of data on emergency room visits, potential missed
visits outside of the UAB health system, and substance abuse
treatment visits. Indeed, when adjustments are made for these
missing data elements, the overall findings of our study do not
change substantially, indicating that our results are robust.
Finally, the findings in our study were derived from actual
health care use activities and medication records at our clinic
and hospital. The relative proportion of medication expendi-
tures and total overall expenditures is remarkably similar to
that found in previous studies conducted in the HAART era,
which used estimates of health care use or models of expen-
ditures, suggesting that our findings are likely to be general-
izable [6, 8, 10, 13, 14].
In summary, the care of patients with HIV infection in the
United States is associated with substantial expenditures that
are driven predominantly by medication costs and are directly
related to stage of disease, as determined by CD4+ cell count
status. Owing to the impact of treatment on improving disease
status, these expenditures are, paradoxically, both decreased by
and driven by the use of antiretroviral medications. The degree
of expenditures generated by clinic and physician fees is quite
meager and is inadequate to cover the cost of care provision
at most HIV clinics in the United States, the majority of which
are subsidized by federal and state dollars. The direct mea-
surement of annual expenditures associated with delivery of
HIV care has important implications for the continued support
of these HIV programs and for the development of future health
care policy in the United States.
Acknowledgments
We acknowledge Dr. Catarina Kiefe and Dr. Norman Weissman for their
thoughtful reviews of this manuscript.
Financial support. National Institutes of Health Centers for AIDS Re-
search (P30-AI27767), National Institutes of Health General Clinical Rec-
ord Center (M01-RR-00032), the University of Alabama at Birmingham
Mary Fisher Clinical AIDS Research and Education Fund, and Glaxo-
SmithKline.
Potential conflicts of interest. M.S.S. has received research support
from Gilead Sciences, GlaxoSmithKline, Panacos, Pfizer/Agouron, Roche
Laboratories, Serono, and Tibotec, is a consultant for Boehringer-Ingel-
heim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Panacos,
Pfizer/Agouron, Roche Laboratories, Tanox, Tibotec/Virco, Trimeris, Ver-
tex, and Mongram Biosciences. All other authors: no conflicts.
References
1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity
and mortality among patients with advanced human immunodefi-
ciency virus infection. HIV Outpatient Study Investigators. N Engl J
Med 1998; 338:853–60.
2. Moore RD, Chaisson RE. Natural history of HIV infection in the era
of combination antiretroviral therapy. AIDS 1999; 13:1933–42.
3. Torres RA, Barr M. Impact of combination therapy for HIV infection
on inpatient census. N Engl J Med 1997; 336:1531–2.
4. Steinbrook R. Providing antiretroviral therapy for HIV infection. N
Engl J Med 2001; 344:844–6.
5. Moore RD, Chaisson RE. Costs to Medicaid of advancing immuno-
suppression in an urban HIV-infected patient population in Maryland.
J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:223–31.
6. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs
of HIV medical care in the era of highly active antiretroviral therapy.
AIDS 1999; 13:963–9.
7. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for
care of HIV-seropositive patients: the impact of highly active antiret-
roviral therapy at a US Veterans Affairs Medical Center. Pharmacoe-
conomics 1999; 16:307–15.
8. Hellinger FJ, Fleishman JA. Estimating the national cost of treating
people with HIV disease: patient, payer, and provider data. J Acquir
Immune Defic Syndr 2000; 24:182–8.
9. Moore RD. Cost effectiveness of combination HIV therapy: 3 years
later. Pharmacoeconomics 2000; 17:325–30.
10. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care
of HIV-infected patients in the era of highly active antiretroviral ther-
apy. N Engl J Med 2001; 344:817–23.
11. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freed-
berg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy
for uninsured HIV-infected adults. Am J Public Health 2001; 91:
1456–63.
12. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness
of combination antiretroviral therapy for HIV disease. N Engl J Med
2001; 344:824–31.
13. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-
1010 • CID 2006:42 (1 April) • HIV/AIDS
term impact of highly active antiretroviral therapy on HIV-related
health care costs. J Acquir Immune Defic Syndr 2001; 27:14–9.
14. Hospital and outpatient health services utilization among HIV-infected
patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30:21–6.
15. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness
implications of the timing of antiretroviral therapy in HIV-infected
adults. Arch Intern Med 2002; 162:2478–86.
16. Medicare physician fee schedule look-up. Available at: http://
www.cms.hhs.gov/apps/pfslookup/. Accessed 3 February 2006.
17. CMS files for download for Medicare payment systems (formerly PUF
files): 2001—payment rates—institutional providers [electronic data
file]. Baltimore, MD: Centers for Medicare and Medicaid Services,
2001.
18. CMS files for download for Medicare payment systems (formerly PUF
files): 2001—payment rates—noninstitutional providers [electronic
data file]. Baltimore, MD: Centers for Medicare and Medicaid Services,
2001.
19. Cohen HE, ed. Drug topics red book. Montvale, NJ: Thomson Medical
Economics, 2001.
20. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment
for adult HIV infection in 2002: updated recommendations of the
International AIDS Society-USA Panel. JAMA 2002; 288:222–35.
21. Fauci AS, Bartlett JG, Goosby EP, Kates J. Guidelines for the use of
antiretroviral agents in HIV-infected adults and adolescents. 4 February
2002. Available at: http://www.aidsinfo.nih.gov/. Accessed 3 February
2006.
22. Waiting for AIDS medications in the United States: an analysis of ADAP
waiting lists. Henry J. Kaiser Family Foundation. Availabe at: http://
www.kff.org/hivaids/hiv 1211504pkg.cfm. Accessed 3 February 2006.
23. National Alliance of State and Territorial AIDS Directors: the ADAP
watch. 10 August 2005. Available at: http://www.nastad.org/documents/
public/policy/publicpolicy/NASTAD_ADAP_Watch_Aug_05-FINAL
.pdf. Accessed 3 February 2006.
